Clinical Trials
Clinical Trial for Idiopathic Pulmonary Fibrosis (IPF)
BEACON-IPF is a global clinical trial evaluating the investigational drug bexotegrast for the treatment of IPF.
For more information on participating in BEACON-IPF, contact us at [email protected].
INTEGRIS-PSC
The INTEGRIS-PSC clinical trial is studying bexotegrast, an oral investigational medicine designed to directly target the development of liver fibrosis (when tissue becomes damaged and scarred, affecting normal function of the organ) in patients with primary sclerosing cholangitis (PSC). The medicine has been tested in over 600 healthy volunteers and patients and was well tolerated. It is taken orally once per day for 12 weeks.
By stopping the cellular process that causes fibrosis, bexotegrast may have the potential to slow or stop the progressive decline in liver function that happens with PSC. This study will help establish the bexotegrast safety profile and provide early insights on whether it affects the progression of the disease.
Enrollment in INTEGRIS-PSC is complete.
Pliant would like to thank our INTEGRIS-PSC clinical sites, investigators and study teams for their assistance in the successful execution of this study. A special thanks to the clinical participants and their families and support networks for helping us advance this important program.
INTEGRIS-IPF
The INTEGRIS-IPF trial is complete.
Based upon the positive data from this trial reported to date, BEACON-IPF has been initiated (scroll up to learn more).
Pliant would like to thank our INTEGRIS-IPF clinical sites, investigators and study teams for their assistance in the successful execution of this study. A special thanks to the clinical participants and their families and support networks for helping us advance this important program.
